



Nutrition and Exercise Treatment of Sarcopenia in Hip Fracture Patients: Systematic Review

Jun-Il Yoo^{1,*}, Yong-Chan Ha^{2,*}, Yonghan Cha³

¹Department of Orthopaedic Surgery, Gyeongang National University Hospital, Gyeongsang National University, Jinju;

²Department of Orthopaedic Surgery, Seoul Bumin Hospital, Seoul;

³Department of Orthopaedic Surgery, Daejeon Eulji Medical Center, Eulji University School of Medicine, Daejeon, Korea

Corresponding author

Yonghan Cha

Department of Orthopaedic Surgery, Daejeon
Eulji Medical Center, 95 Dunsanse-ro,
Seo-gu, Daejeon 35233, Korea
Tel: +82-42-611-3280
Fax: +82-42-611-3283
E-mail: naababo@hanmail.net

Received: February 9, 2022

Revised: March 2, 2022

Accepted: March 3, 2022

*Jun-Il Yoo and Yong-Chan Ha contributed
equally to this work and should be
considered co-first author.

Background: This study aimed to investigate nutritional or rehabilitation intervention protocols for hip fracture patients with sarcopenia and to analyze the effect of these protocols through a systematic review of studies that reported clinical results. **Methods:** Studies were selected based on the following criteria: (1) study design: randomized controlled trials or non-randomized comparative studies; (2) study population: patients with hip fracture; (3) intervention: nutritional or rehabilitation; and (4) reporting the clinical outcomes and definition of sarcopenia. **Results:** Of the 247 references initially identified from the selected databases, 5 randomized controlled studies and 2 comparative studies were selected for further investigation. The total number of patients was 497. We found 2 specific rehabilitation interventions, one medication intervention using erythropoietin, and 4 nutritional interventions using amino-acid or protein. Among the studies included in this systematic review, 2 studies did not find a clear statistical difference in assessment tools compared to controls after intervention. On the other hand, the rest of the studies positively interpreted the results for intervention. The most frequently used assessment tool for intervention was handgrip strength. **Conclusions:** Although mainstream methods of intervention for sarcopenia include nutritional, exercise, and drug interventions, the validity of these interventions in elderly hip fractures has not been clearly proven. In addition, as most studies only reported short-term results, there is no consensus on the optimal long-term treatment.

Key Words: Aged · Exercise · Hip fractures · Nutritional status · Sarcopenia

INTRODUCTION

Sarcopenia is a geriatric syndrome defined by a progressive impairment of muscle function due to the loss of skeletal muscle mass.[1-6] Sarcopenia increases the risk of falling and is associated with osteoporosis and hip fracture.[7,8] Compared with hip fracture patients without sarcopenia, those with sarcopenia accompanied more pain after surgery, had decreased compliance with weight-bearing, and resulted in a higher rate of physically and functionally deficient state.[9,10] Therefore, sarcopenia is one of many problems requiring treatment in elderly patients with hip fractures.

There have been various reports on the results of nutritional support and specific exercise or rehabilitation in sarcopenia patients.[11,12] Nutritional support and exercise appear to be effective in preventing or treating sarcopenia. However,

Copyright © 2022 The Korean Society for Bone and Mineral Research

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

the protocols of nutritional and rehabilitation interventions are different for each study, and it is difficult to determine the effectiveness depending on the characteristics of the group.[1] Also, research on whether treatment for sarcopenia is effective in elderly hip fracture patients with reduced digestive or cognitive function is scarce.[2] Nevertheless, sarcopenia is an important factor influencing the outcome of treatment for hip fracture patients, thus, a study on effective treatment is essential.[2]

Therefore, the purpose of this study is to (1) investigate nutritional or rehabilitation intervention protocols; and (2) to analyze the effect of these protocols through a systematic review of studies that report on clinical results of hip fracture patients with sarcopenia.

METHODS

Our current systematic review was performed according to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guideline.[13]

1. Study eligibility criteria

Studies were selected based on the following criteria: (1) study design: randomized controlled trials (RCTs) or non-randomized comparative studies; (2) study population: patients with hip fracture; (3) intervention: nutritional or rehabilitation intervention; and (4) reporting the clinical outcomes and definition of sarcopenia. Studies were excluded if they failed to meet the criteria.

2. Search methods for identification of studies

A comprehensive search of all relevant RCTs and comparative studies was conducted through PubMed Central, OVID Medline, Cochrane Collaboration Library, Web of Science, EMBASE, KoreaMed, and AHRQ, up to April 2021, with English language restriction. We used the following search terms: (("sarcopenia"[MeSH Terms] OR "sarcopenia"[All Fields]) AND ("hip fractures"[MeSH Terms] OR ("hip"[All Fields] AND "fractures"[All Fields]) OR "hip fractures"[All Fields] OR ("hip"[All Fields] AND "fracture"[All Fields]) OR "hip fracture"[All Fields])). A manual search of possibly related references was also conducted. Two investigators independently reviewed the titles, abstracts, and full texts of all potentially relevant studies, as recommended by the Cochrane Collaboration.[14]

3. Data extraction

The following data were extracted from the included articles: authors, publication date, study design, characteristics of the participants, follow-up period, specific interventions, and outcome measurements.

4. Methodological quality assessment

Two authors independently assessed the methodological quality of included studies using the same criteria for RCTs and as described in the Cochrane Handbook for Systematic Reviews of Interventions 5.2. The criteria include the following: (1) Allocation concealment; (2) Were the inclusion and exclusion criteria clearly defined?; (3) Were the outcomes of patients who withdrew or were excluded after allocation described and included in an intention-to-treat analysis?; (4) Were the groups well-matched with appropriate covariate adjustments?; (5) Did the surgeons have experience in the operations performed in the trial, prior to its commencement?; (6) Were the care programs other than the trial options identical?; (7) Were all the outcome measures clearly defined in the text with a definition of any ambiguous terms encountered?; (8) Were the outcome assessors blinded to assignment status?; (9) Was the timing of outcome measures appropriate?; and (10) Were follow-up losses reported and if so, were they less than 5% of participants lost from follow-up?

The Newcastle-Ottawa scale was used to assess the methodological quality of non-randomized studies. The scale contains 8 items, which are categorized into 3 dimensions: the selection of the study population, the comparability of the groups, and the ascertainment of the exposure (case-control study) or outcome (cohort study). Each dimension consists of subcategorized questions: selection (a maximum of 4 stars), comparability (a maximum of 2 stars), and exposure or outcome (a maximum of 3 stars).[15,16] Apparently, a study can be awarded a maximum of 9 stars, which indicates the highest quality. In the present study, 2 authors independently evaluated the quality of all the studies.

RESULTS

The initial search identified 247 references from the selected databases. The 203 references were excluded by screening the abstracts and titles for duplicates, unrelated articles, case reports, systematic reviews, and non-compara-

tive studies. The remaining 17 studies underwent full-text review and subsequently, 10 studies were excluded. The details of the identification of relevant studies are shown in the flow chart of the study selection process (Fig. 1). Five RCTs and 2 comparative studies were selected for further investigation. The total number of patients was 497 (RCTs, 279; comparative studies, 221). Five studies included patients ≥ 65 years of age, and 2 studies included patients ≥ 60 years of age. There were 3 studies that applied the Asian working group criteria for the definition of sarcopenia.[2,3,17]

The main characteristics and outcomes of the studies included in this systematic review are presented in Table 1. [1-5,8,17] Two studies conducted specific rehabilitation intervention and 1 study conducted intervention using erythropoietin drugs.[2,3,17] Oh et al. [3] applied an antigravity treadmill combined with conventional rehabilitation to hip fracture patients. Antigravity treadmill was applied with 50% to 60% of body weight administered at a rate of 1.5 mph for 20 min based on a weekday. After that, the proportion of body weight and speed of the antigravity treadmill was increased step by step. Lim et al. [17] analyzed the effect of the fragility fracture integrated rehabilitation management (FIRM) program. The FIRM program consists of 10 days of physical therapy (2 60-min sessions per day), 4 days of occupational therapy, fall prevention education, discharge

planning, and referral to community-based care during the-2 week hospital stay after surgery. Zhang et al. [2] administered intravenous erythropoietin to intertrochanteric fracture patients for 10 days after surgery.

Four studies conducted nutritional interventions using amino-acid or protein, although there were differences in composition, dose, and duration of intervention.[1,4,5,8] Malafarina et al. [8] provided supplements consisting of protein-fat carbohydrates, and Flodin et al. [5] provided protein with calcium and vitamin D for sarcopenia patients. In the studies of de Sire et al. [4] and Invernizzi et al. [1], patients received a 2-month amino acid supplementation.

The most frequently used assessment tool for intervention was handgrip strength (Table 2).[1-5] In addition, ambulatory functions such as the Koval score, timed up and go, body composition measured by dual energy X-ray absorptiometry, and appendicular skeletal muscle mass was used. Among the studies included in this systematic review, 2 studies did not find a clear statistical difference in assessment tools compared to controls after intervention.[4,5] However, the rest of the studies positively interpreted the effect of results for intervention. The Newcastle-Ottawa scale was used to assess the quality of the selected studies. All included studies scored 6 to 8 points, indicating relatively high quality.




Fig. 1. Flowchart according to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guideline. RCT, randomized controlled trial.

Table 1. Baseline characteristics of included studies

| References | Year | Study design | Inclusion criteria | Diagnosis criteria of sarcopenia | No. of hip fractures | Type of intervention | Intervention | |
|--------------------|------|---|--|----------------------------------|----------------------|----------------------|--|--|
| | | | | | | | Controls | Treatment group |
| Oh et al. [3] | 2020 | Prospective RCT | Age 65-90, sarcopenia, after hip Fx. surgery | AWG | 38 | Rehabilitation | Conventional rehabilitation (30 min from physical therapist on each of the 10 consecutive working days. Passive hip and knee mobilization, strengthening of the hip abductor and extensor muscles, transfer, and gait training on the floor and stairs during every session) | AGT combined with conventional rehabilitation in the first week (on days 1-5). AGT was applied with 50-60% of body weight administered at a rate of 1.5 mph during 20 min based on weekday. In the following weeks (on days 6-10), patients received AGT for 20 min, with 70-80% of body weight administered at a rate of 1.5-1.8 mph |
| de Sire et al. [4] | 2020 | Prospective RCT | Age ≥ 65, 3 months after THA for hip Fx | EWG | 20 | Nutrition | Specific physical exercise rehabilitative program, consisting of 5 sessions of 40 min each (15 min of walking training, 10 min of upper and lower limb strengthening and stretching, and 10 min of balance exercises) per week for 2 weeks under the supervision of an experienced physical therapist, and, subsequently, a home-based exercise protocol (aerobic, flexibility, resistance, and neuromotor) without physical therapist supervision | Patients received a 2-month amino acid supplementation (Aminotrophic®, Errekappa Euroterapici Spa, Milan, Italy), 2 sachets of 4 g daily (1,250 mg of Leucine, 650 mg of L-lysine; 625 mg of L-isoleucine, 625 mg of L-valine, 350 mg of L-threonine, 150 mg of L-cystine, 150 mg of L-histidine, 100 mg of L-phenylalanine, 50 mg of L-methionine, 30 mg of L-tyrosine, 20 mg of L-tryptophan; 0.15 mg of vitamin B6, and 0.15 mg of vitamin B1) with specific physical exercise rehabilitative program |
| Zhang et al. [2] | 2020 | Retrospective comparative study | Age >60, after intertrochanteric Fx. surgery, sarcopenia | AWG | 141 | Medication | | Patients received the erythropoietin intravenous injection (10,000 IU) once per day on the day of surgery and then continuously for 10 days. Recombinant human erythropoietin injection (CHO cell, Shenyang Sansheng Pharmaceutical, Shenyang, China) |
| Lim et al. [17] | 2019 | Prospective observational comparative study | Age >65, femoral neck Fx | AWG | 80 | Rehabilitation | | The fragility FIRM program during 2 weeks hospital stay after surgery. The FIRM program consists of 10 days of physical therapy (2 sessions of 60-min per day), 4 days of OT, fall prevention education, discharge planning, and referral to community-based care during the 2-week hospital stay after surgery. During the FIRM program, physical therapy (weight-bearing exercises, strengthening exercises, gait training, aerobic exercise, and functional training) gradually progressed based on the individual's functional level; OT for activity of daily living (transfer, sit-to-stand, bed mobility, dressing, self-care, and use of adaptive equipment) was also provided. Intensive education-based on an hip Fx. care manual was provided for patients and their families by members of the multidisciplinary rehabilitation team |

(Continued to the next page)

Table 1. Continued

| References | Year | Study design | Inclusion criteria | Diagnosis criteria of sarcopenia | No. of hip fractures | Type of intervention | Controls | Intervention | Treatment group |
|-----------------------|------|-----------------------------|---|----------------------------------|----------------------|----------------------|---|--|-----------------|
| Invernizzi et al. [1] | 2019 | Prospective RCT | Age >65, 3 months after hip Fx. surgery | EWG | 32 | Nutrition | Physical exercise rehabilitative program (5 sessions of 40 min/week for 2 weeks, followed by a home-based exercise protocol). The first phase of each session consisted of 15 min of walking training, the second phase consisted of 10 min of upper and lower limb strengthening and stretching, standing or at bed, and the fourth phase consisted of 10 min of balance exercises. Each session lasted 40 min and was performed with the supervision of an experienced physiotherapist. After these first 2 weeks of physical exercise rehabilitative program, all participants performed a home-based exercise. Protocol up to the end of the study period, after 2 months of intervention | Physical exercise rehabilitative program (5 sessions of 40 min/week for 2 weeks, followed by a home-based exercise protocol) and received a dietetic counseling, supplemented with 4 g/day of essential amino acids (Aminotrofic [®] , Errekappa Euroterapici Spa), Patients in group A were treated for 2 months with an essential amino acid supplementation (Aminotrofic [®]) 2 sachets of 4 g per day (1,250 mg of l-leucine, 650 mg of l-lysine; 625 mg of l-isoleucine, 625 mg of l-valine, 350 mg of l-threonine, 150 mg of l-cystine, 150 mg of l-histidine, 100 mg of l-phenylalanine, 50 mg of l-methionine, 30 mg of l-tyrosine, 20 mg of l-tryptophan; 0.15 mg of vitamin B6, and 0.15 mg of vitamin B1) | |
| Malafarina et al. [8] | 2017 | Multicenter prospective RCT | Age >65, after hip Fx. surgery | EWG | 107 (drop-out 15) | Nutrition | Rehabilitation therapy comprised 2 distinct parts. The first part took place in the hospital ward (nursing staff and occupational therapist) and was based on moving patients early using technical aids (canes, crutches, or walker), and rehabilitation of activities of daily living. The second part (physical therapy) took place at the hospital gym and included exercises to strengthen the lower limbs, balance exercises and walking re-training in individual or group 50 min sessions, once a day 5 days a week (Monday to Friday) | Rehabilitation therapy with standard diet plus oral nutritional supplementation in the form of 2 bottles a day of HMB. The nutritional characteristics of the standard diet are: 1,500 Kcal, 23.3% protein (87.4 g/day), 35.5% fat (59.3 g/day) and 41.2% carbohydrates (154.8 g/day). In addition, patients in the IG received 2 bottles a day (1 in the morning and 1 in the afternoon) of prepared oral liquid nutritional supplementation (220 mL x 2, total: 660 Kcal) (Ensure [®] Plus Advance, Abbott Laboratories, Chicago, IL, USA) with the following nutritional characteristics: 1.5 Kcal/mL, 24% protein (9.1 g/100 mL), 29% fat (5 g/100 mL) and 46% carbohydrates (16.8 g/100 mL). The supplement was enriched with CaHMB 0.7 g/100 mL, 25(OH)D 227 IU/100 mL and 227 mg/100 mL of calcium | |
| Flodin et al. [5] | 2015 | Prospective RCT | Age >60, after hip Fx. surgery | EWG | 79 | Nutrition | Received calcium 1 g and vitamin D 800 IE, specifically, cholecalciferol (Calcichew-D3 [®] , Takeda Pharmaceutical Company Limited, Osaka, Japan) divided into 2 daily doses for 12 months | Ca, vitamin D + Risedronate + nutritional supplement a 200 mL package twice daily, each containing 20 g of protein and 300 Kcal (Fresubin [®] , Fresenius Kabi, Bad Homburg, Germany). This supplement was given for the first 6 months following hip Fx | |

RCT, randomized controlled trial; Fx, fracture; THA, total hip arthroplasty; AWG, Asian Working Group; HMB, β-hydroxy-β-methylbutyrate; AGT, antigravity treadmill; FRM, fracture integrated rehabilitation management; OT, occupational therapy.

Table 2. Patient characteristics and assessment methods for intervention and conclusions of included studies

| References | Intervention | No. of hip fractures | No. of sarcopenia | Age | Sex (F:M) | Height (cm) | Weight (kg) | BMI (g/m ²) | Assessment methods | Conclusions |
|-----------------------|--------------|----------------------|-------------------|--------------|-----------|---------------|---------------|-------------------------|--|---|
| Oh et al. [3] | Controls | 19 | 19 | 81.15 ± 4.9 | 13:6 | 157.73 ± 7.53 | 52.08 ± 11.62 | 20.93 ± 4.54 | Koval walking ability scores functional ambulatory category, Berg Balance Scale, Korean version of Mini-Mental State Examination, Euro Quality of Life Questionnaire Five-Dimensional Classification, Korean version of modified Barthel index, and grip strength | Both groups were improved after intervention. As additional benefits were evident among those who carried out anti-gravity treadmill, it may be appropriate for patients with sarcopenia after hip fracture surgery |
| | Treatments | 19 | 19 | 76.94 ± 9.43 | 13:6 | 160.08 ± 8.25 | 55.51 ± 11.15 | 21.58 ± 3.23 | | |
| de Sire et al. [4] | Controls | 10 | 8 | 77.65 ± 8.4 | 8:2 | | | | Serum myostatin level, skeletal muscle mass index, obtained by whole-body tetrapolar bioelectrical impedance analysis (BIA 101 Anniversary Sport Edition, Akern Srl, Florence, Italy); appendicular muscle strength, measured by hand-grip strength test (hand-held Jamar [®] dynamometer); and physical performance, using the TUG | In this proof of principle study, we found a significant intragroups difference in terms of serum myostatin levels in both groups. On the other hand, we found no significant differences between groups in serum myostatin levels at the end of treatment, probably due to the correlation between physical exercise protocol and myostatin levels, independently from amino acids supplementation |
| | Treatments | 10 | 7 | 80.33 ± 6.72 | 9:1 | | | | | |
| Zhang et al. [2] | Controls | 33 | 33 | 78.63 ± 7.28 | 33:0 | | | | Appendicular skeletal muscle mass, hand-grip strength measurement, Hemoglobin level | Erythropoietin can improve the muscle strength of female patients with sarcopenia during the perioperative period, and increase muscle mass both of women and men |
| | Controls | 22 | 22 | 75.01 ± 8.2 | 0:22 | | | | | |
| | Treatments | 44 | 44 | 79.54 ± 6.2 | 44:0 | | | | | |
| Lim et al. [17] | Controls | 45 | 0 | 79.7 ± 6.5 | 34:11 | 157.6 ± 7.1 | 56.7 ± 8.1 | 22.9 ± 3.5 | Main outcomes for ambulatory function (Koval score, Functional Ambulatory Category) and other secondary outcomes were measured at rehabilitation admission, at discharge, at 3 months and 6 months after surgery. Other secondary outcomes were measured. The possibility of independent ambulation at 6 months after surgery were also investigated | The fragility fracture integrated rehabilitation management program was effective for promoting functional recovery in older patients with fragility hip fracture, either with or without sarcopenia |
| | Treatments | 35 | 35 | 82.8 ± 7.5 | 28:7 | 153.6 ± 8.4 | 48.5 ± 9.1 | 21.2 ± 3.4 | | |
| Invernizzi et al. [1] | Controls | 16 | 12 | 77.65 ± 8.4 | 14:3 | | | 23.15 ± 5.33 | Hand-grip strength, TUG, and low Level of Assistance Scale | A multidisciplinary rehabilitative and nutritional intervention seems to be effective on functioning in hip fracture patients, in particular sarcopenic ones |
| | Treatments | 16 | 11 | 80.33 ± 6.72 | 13:2 | | | 23.05 ± 4.77 | | |

(Continued to the next page)

Table 2. Continued

| References | Intervention | No. of hip fractures | No. of sarcopenia | Age | Sex (F:M) | Height (cm) | Weight (kg) | BMI (g/m ²) | Assessment methods | Conclusions |
|-----------------------|------------------------|----------------------|-------------------|-----------------------------|-----------------------|------------------------|----------------------------|--------------------------------------|---|--|
| Malafarina et al. [8] | Controls Treatments | 43 49 | | 84.7 ± 6.3 85.7 ± 6.5 | 35:9 33:10 | 160 ± 1.0 160 ± 1.0 | 63.2 ± 14.7 62.7 ± 12.9 | 26 ± 5.4 24.9 ± 4.4 | Body mass index, anthropometric parameters, Barthel index and the Functional Ambulation Categories score. Muscle mass was assessed using bioelectrical impedance analysis, which allowed us to calculate appendicular lean mass | A diet enriched in HMB improves muscle mass, prevents the onset of sarcopenia and is associated with functional improvement in elderly patients with hip fractures. Orally administered nutritional supplements can help to prevent the onset of sarcopenic obesity |
| Flodin et al. [5] | Controls Treatments | 25 28 26 | | 78 ± 11 80 ± 9 81 ± 8 | 19:6 18:10 19:7 | | | 22.4 ± 2.6 24 ± 2.9 22.7 ± 3.4 | Body composition as measured by dual-energy X-ray absorptiometry. HGS and HRQoL were registered at baseline, 6 and 12 months postoperatively | Protein-rich nutritional supplementation was unable to preserve fat-free mass index more effectively than vitamin D and calcium alone, or combined with bisphosphonate, in this relatively healthy group of hip fracture patients. However, trends toward positive effects on both HGS and HRQoL were observed following nutritional supplementation |

The data is presented as mean ± standard deviation. F, female; M, male; BMI, body mass index; TUG, Timed Up and Go test; HGS, hand-grip strength; HRQoL, health-related quality of life; HMB, β-hydroxy-β-methylbutyrate.

DISCUSSION

Approximately 40% of elderly people with a fracture do not recover their previous functional status.[18] Functional loss is associated with institutionalization and increases mortality.[18] Bed confinement and the reduced mobility of hospitalized elderly patients are associated with loss of muscle mass and function.[19] In addition, age-related muscle loss occurs in elderly patients.[5] It has been reported that about 5% to 6% of muscle loss occurs within 1 year after hip fracture.[20] Thus, the prevalence of sarcopenia in elderly patients with hip fractures is up to 54%.[21]

The pathogenesis of sarcopenia is linked to an alteration of the homeostasis between protein anabolism and catabolism in the muscle tissue, resulting in the progressive reduction of the muscle mass.[22] This homeostasis is affected by several factors. Inflammatory cytokines, cortisol, myostatin, and the over-expression of the ubiquitin-proteasome pathway promotes muscle tissue degradation, while adequate protein or amino acid intake, growth hormone, and insulin growth factor-1 promote the synthesis of new muscle tissue.[22] Thus, mainstream methods of intervention for sarcopenia include nutritional intervention, exercise intervention and drug intervention.[2]

1. Results and limitations of studies related to rehabilitation

Oh et al. [3] applied an antigravity treadmill combined with conventional rehabilitation for 10 days after surgery in hip fracture patients with sarcopenia. Although functional scores, such as Koval score and Berg Balance Scale, improved at postoperative 3 to 6 months, they plateaued in the subsequent period. They concluded that rehabilitation with an antigravity treadmill provided additional benefit to hip fracture patients, but there is no improvement in handgrip strength. Lim et al. [17] operated an elaborate rehabilitation program for about 10 days on patients who underwent hip fracture surgery and reported the following clinical results. They insisted that the ambulatory function, assessed through Koval score, Functional Ambulatory and Category scale, of the patients investigated up to 6 months after surgery was improved by this rehabilitation program regardless of the presence of sarcopenia. However, no significant improvement in handgrip strength was observed in this study as well.

Although improvement in functional score was observed in both studies, several factors could be considered for the fact that there was no change in handgrip strength, an index related to sarcopenia. First, exercise for 10 days after surgery is considered too short to improve sarcopenia. In Lim et al.'s study [17], even considering the degree of complication due to hip fracture, 61.5% to 70% of patients who recovered to their pre-injury (fracture) ambulatory function still displayed muscle loss. Moderate to high-intensity resistance exercises can improve muscle mass and strength, and improve body muscle function.[2] We believe that additional research is needed on the intensity and duration of exercise that can increase muscle mass in hip fracture patients, and a change in rehabilitation protocol is required in consideration. Second, it is possible that the failure of social or familial support for rehabilitation after surgery may have affected the patients' sarcopenia status. Third, there was no support for nutritional status in both studies.

2. Results and limitations of studies related to nutrition

In the studies of de Sire et al. [4] and Invernizzi et al. [1], 2 months of amino acid supplementation were performed. The main components of the amino acids used were L-leucine, L-lysine, and L-valine, with addition of vitamin B6 and vitamin B1. In the study by Malafarina et al. [8], patients were supplemented with 2 bottles per day of β -hydroxy- β -methylbutyrate (HMB), a metabolite of leucine, during hospitalization. In the study of Fitschen et al. [23], HMB has been shown to improve the synthesis and reduce the degradation of muscle proteins. The endogenous output of HMB reduces with age and its levels are associated with the loss of appendicular lean mass and handgrip strength. [24] In the study of Kuriyan et al. [24], supplementation with HMB prevents muscle loss associated with bed confinement. Branched-chain amino acids, such as leucine, are responsible for the activation of muscle metabolism by stimulating the mammalian target of rapamycin.[25]

De Sire et al. [4] measured serum myostatin levels after amino acid supplementation, but myostatin levels decreased regardless of intervention, and there was no difference between the 2 groups. Invernizzi et al. [1] reported that handgrip strength, Timed Up and Go test, and Iowa Level of Assistance scale was improved only in hip fracture patients with sarcopenia among patients who received

nutritional support, but in patients without sarcopenia, improvement was not observed. In the study of Malafarina et al. [8], the intervention group undergone HMB supplementation lost weight at discharge compared to the time of admission, but to a lesser degree compared to the control group. The appendicular lean mass did not decrease in the intervention group compared to at the time of hospitalization.

The low concentration of vitamin D is associated with a reduction in muscle mass and strength, and supplementation with vitamin D is effective in the prevention and management of frailty.[26] In the studies of Artaza-Artabe et al. [26] and Flodin et al. [5], calcium and vitamin D was included in nutritional supplements. Interestingly, in the study of Flodin et al. [5], although protein-rich nutritional supplementation positively affects handgrip strength and quality of life, there was no difference in change in fat-free mass index and handgrip strength between the control group (only calcium and vitamin D) and the intervention group (calcium and vitamin D, protein, and risedronate). Also, the period of nutritional supplement was 6 months. As far as we know there have not been any nutritional intervention trials persisting longer than six months for hip fracture patients. Two possible explanations for the lack of significant benefits may be that: poor nutritional state prior to hip fracture; prolonged catabolic state, in which metabolic, hormonal, and inflammatory response to injury and operation result in an accelerated breakdown of muscle protein.[27-29]

In the studies of de Sire et al. [4] and Invernizzi et al. [1], the duration of rehabilitation was 2 weeks, and in the study of Malafarina et al. [8], exercise was performed for 5 days per week during hospitalization. A study by Flodin et al. [5] reported that conventional rehabilitation aimed at restoring the ability to walk was performed, but did not describe how long it was performed. Although nutrients and, in particular amino acids, play a key role in muscle metabolism and functioning in older people, all studies performed nutritional support and rehabilitation simultaneously. All studies reported that nutritional intervention reduced muscle mass loss, but it does not seem to completely prevent muscle mass loss, because of the short-term intervention. In addition, since the rehabilitation and nutrition protocols, methods for evaluating the effectiveness of interventions differed for each study, thus it was not possible to conclude

which method was the most effective.

3. Results and limitations of studies related to medication

Patients' comorbidity and cognitive impairment will worsen over time after hip fracture. In addition, complications of hip fracture, and pain caused by fracture itself and following surgical interventions interfere with ambulation. These can make rehabilitation or exercise difficult to sustain. Even if long-term nutritional support is provided, if continuous rehabilitation is limited, the effectiveness of nutritional support seems to be also limited. Therefore, although there is no drug proven to date, it is necessary to develop a drug that can directly affect myocytes. Erythropoietin has been reported to have therapeutic effects such as anti-apoptosis, anti-oxidation, anti-inflammation and maintenance of vascular structure, as well as a normal function.[30-32]

Zhang et al. [2] administered erythropoietin to intertrochanteric fracture patients over 60 years after surgery by classifying groups according to the presence or absence of sarcopenia and sex. They reported that erythropoietin increased handgrip strength in sarcopenic women compared to the control group, although there was no effect in sarcopenic men. They also reported that the appendicular skeletal muscle increment of the intervention group was markedly increased regardless of sex. Therefore, they insisted that erythropoietin can improve the muscle strength of female patients with sarcopenia during the perioperative period and increase muscle mass both of women and men, with erythropoietin possibly improving the symptoms of sarcopenia. Moreover, even more surprising in the study was that administration of erythropoietin reduced postoperative complications and length of stay. However, in this study, muscle strength increase due to erythropoietin was not observed in men, and they did not evaluate the reduction state of the fracture, the leg length discrepancy caused by the collapse of the fracture site, and postoperative ambulatory state. In addition, since cost effectiveness and safety for complications by erythropoietin have not been proven, caution is needed in the use of erythropoietin.

There are limitations to our study. First, because the characteristics of patients included, such as race and age, are heterogenous, the definition or measuring methods for sarcopenia in each study are different. Therefore, it may be

difficult to use the protocols introduced in this study in general. Second, because the number of studies that performed intervention for the treatment of sarcopenia in patients with hip fracture was small and there were many differences between the protocols, we could not find proper intervention protocol for sarcopenia in patients with hip fracture. It is considered that further research is needed in the future.

CONCLUSION

Although mainstream methods of intervention for sarcopenia include nutritional intervention, exercise intervention and drug intervention, the validity of these interventions in elderly hip fractures has not been proven clearly. Also, most studies have reported short-term results, there is no consensus on optimal long-term treatment.

DECLARATIONS

Funding

This research was supported by a grant from the Korean Health Technology R & D Project through the Korean Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI19C0481, HC20C0157). And, this work was supported by Biomedical Research Institute Fund (GNUHBRIF-2018-0008) from the Gyeongsang National University Hospital.

Ethics approval and consent to participate

Not applicable.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

ORCID

Jun-Il Yoo <https://orcid.org/0000-0002-3575-4123>
 Yong-Chan Ha <https://orcid.org/0000-0002-6249-0581>
 Yonghan Cha <https://orcid.org/0000-0002-7616-6694>

REFERENCES

1. Invernizzi M, de Sire A, D'Andrea F, et al. Effects of essential amino acid supplementation and rehabilitation on func-

- tioning in hip fracture patients: a pilot randomized controlled trial. *Aging Clin Exp Res* 2019;31:1517-24. <https://doi.org/10.1007/s40520-018-1090-y>.
2. Zhang Y, Chen L, Wu P, et al. Intervention with erythropoietin in sarcopenic patients with femoral intertrochanteric fracture and its potential effects on postoperative rehabilitation. *Geriatr Gerontol Int* 2020;20:150-5. <https://doi.org/10.1111/ggi.13845>.
 3. Oh MK, Yoo JI, Byun H, et al. Efficacy of combine anti-gravity treadmill and conventional rehabilitation after hip fracture in patients with sarcopenia. *J Gerontol A Biol Sci Med Sci* 2020;75:e173-81. <https://doi.org/10.1093/geron/glaa158>.
 4. de Sire A, Baricich A, Renò F, et al. Myostatin as a potential biomarker to monitor sarcopenia in hip fracture patients undergoing a multidisciplinary rehabilitation and nutritional treatment: a preliminary study. *Aging Clin Exp Res* 2020;32:959-62. <https://doi.org/10.1007/s40520-019-01436-8>.
 5. Flodin L, Cederholm T, Säaf M, et al. Effects of protein-rich nutritional supplementation and bisphosphonates on body composition, handgrip strength and health-related quality of life after hip fracture: a 12-month randomized controlled study. *BMC Geriatr* 2015;15:149. <https://doi.org/10.1186/s12877-015-0144-7>.
 6. Doherty TJ. Invited review: Aging and sarcopenia. *J Appl Physiol* (1985) 2003;95:1717-27. <https://doi.org/10.1152/jappphysiol.00347.2003>.
 7. Di Monaco M, Vallero F, Di Monaco R, et al. Prevalence of sarcopenia and its association with osteoporosis in 313 older women following a hip fracture. *Arch Gerontol Geriatr* 2011;52:71-4. <https://doi.org/10.1016/j.archger.2010.02.002>.
 8. Malafarina V, Uriz-Otano F, Malafarina C, et al. Effectiveness of nutritional supplementation on sarcopenia and recovery in hip fracture patients. A multi-centre randomized trial. *Maturitas* 2017;101:42-50. <https://doi.org/10.1016/j.maturitas.2017.04.010>.
 9. Sherrington C, Lord SR, Herbert RD. A randomized controlled trial of weight-bearing versus non-weight-bearing exercise for improving physical ability after usual care for hip fracture. *Arch Phys Med Rehabil* 2004;85:710-6. [https://doi.org/10.1016/s0003-9993\(03\)00620-8](https://doi.org/10.1016/s0003-9993(03)00620-8).
 10. Landi F, Calvani R, Ortolani E, et al. The association between sarcopenia and functional outcomes among older patients with hip fracture undergoing in-hospital rehabilitation. *Osteoporos Int* 2017;28:1569-76. <https://doi.org/10.1007/s00198-017-3929-z>.
 11. Beaudart C, Dawson A, Shaw SC, et al. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. *Osteoporos Int* 2017;28:1817-33. <https://doi.org/10.1007/s00198-017-3980-9>.
 12. Churilov I, Churilov L, MacIsaac RJ, et al. Systematic review and meta-analysis of prevalence of sarcopenia in post acute inpatient rehabilitation. *Osteoporos Int* 2018;29:805-12. <https://doi.org/10.1007/s00198-018-4381-4>.
 13. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol* 2009;62:e1-34. <https://doi.org/10.1016/j.jclinepi.2009.06.006>.
 14. Beudet K. The cochrane collaboration and meta-analysis of clinical data. *Am Orthopt J* 2010;60:6-8. <https://doi.org/10.3368/aoj.60.1.6>.
 15. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010;25:603-5. <https://doi.org/10.1007/s10654-010-9491-z>.
 16. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60. <https://doi.org/10.1136/bmj.327.7414.557>.
 17. Lim SK, Beom J, Lee SY, et al. Functional outcomes of fragility fracture integrated rehabilitation management in sarcopenic patients after hip fracture surgery and predictors of independent ambulation. *J Nutr Health Aging* 2019;23:1034-42. <https://doi.org/10.1007/s12603-019-1289-4>.
 18. Uriz-Otano F, Uriz-Otano JI, Malafarina V. Factors associated with short-term functional recovery in elderly people with a hip fracture. Influence of cognitive impairment. *J Am Med Dir Assoc* 2015;16:215-20. <https://doi.org/10.1016/j.jamda.2014.09.009>.
 19. Vellas B, Fielding R, Miller R, et al. Designing drug trials for sarcopenia in older adults with hip fracture - a task force from the international conference on frailty and sarcopenia research (ICFSR). *J Frailty Aging* 2014;3:199-204. <https://doi.org/10.14283/jfa.2014.24>.
 20. Fox KM, Magaziner J, Hawkes WG, et al. Loss of bone density and lean body mass after hip fracture. *Osteoporos Int* 2000;11:31-5. <https://doi.org/10.1007/s001980050003>.
 21. Kuhls DA, Rathmacher JA, Musngi MD, et al. Beta-hydroxy-

- beta-methylbutyrate supplementation in critically ill trauma patients. *J Trauma* 2007;62:125-31; discussion 31-2. <https://doi.org/10.1097/TA.0b013e31802dca93>.
22. White TA, LeBrasseur NK. Myostatin and sarcopenia: opportunities and challenges - a mini-review. *Gerontology* 2014;60:289-93. <https://doi.org/10.1159/000356740>.
 23. Fitschen PJ, Wilson GJ, Wilson JM, et al. Efficacy of β -hydroxy- β -methylbutyrate supplementation in elderly and clinical populations. *Nutrition* 2013;29:29-36. <https://doi.org/10.1016/j.nut.2012.05.005>.
 24. Kuriyan R, Lokesh DP, Selvam S, et al. The relationship of endogenous plasma concentrations of β -Hydroxy β -Methyl Butyrate (HMB) to age and total appendicular lean mass in humans. *Exp Gerontol* 2016;81:13-8. <https://doi.org/10.1016/j.exger.2016.04.013>.
 25. Rizzoli R, Stevenson JC, Bauer JM, et al. The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). *Maturitas* 2014;79:122-32. <https://doi.org/10.1016/j.maturitas.2014.07.005>.
 26. Artaza-Artabe I, Sáez-López P, Sánchez-Hernández N, et al. The relationship between nutrition and frailty: Effects of protein intake, nutritional supplementation, vitamin D and exercise on muscle metabolism in the elderly. A systematic review. *Maturitas* 2016;93:89-99. <https://doi.org/10.1016/j.maturitas.2016.04.009>.
 27. Ljungqvist O, Soop M, Hedström M. Why metabolism matters in elective orthopedic surgery: a review. *Acta Orthop* 2007;78:610-5. <https://doi.org/10.1080/17453670710014293>.
 28. Bell J, Bauer J, Capra S, et al. Barriers to nutritional intake in patients with acute hip fracture: time to treat malnutrition as a disease and food as a medicine? *Can J Physiol Pharmacol* 2013;91:489-95. <https://doi.org/10.1139/cjpp-2012-0301>.
 29. Hébuterne X, Bermon S, Schneider SM. Ageing and muscle: the effects of malnutrition, re-nutrition, and physical exercise. *Curr Opin Clin Nutr Metab Care* 2001;4:295-300. <https://doi.org/10.1097/00075197-200107000-00009>.
 30. Ostrowski D, Heinrich R. Alternative erythropoietin receptors in the nervous system. *J Clin Med* 2018;7:24. <https://doi.org/10.3390/jcm7020024>.
 31. Cheng CW, Solorio LD, Alsberg E. Decellularized tissue and cell-derived extracellular matrices as scaffolds for orthopaedic tissue engineering. *Biotechnol Adv* 2014;32:462-84. <https://doi.org/10.1016/j.biotechadv.2013.12.012>.
 32. Lamon S, Russell AP. The role and regulation of erythropoietin (EPO) and its receptor in skeletal muscle: how much do we really know? *Front Physiol* 2013;4:176. <https://doi.org/10.3389/fphys.2013.00176>.

